Cancer Immunotherapy Market to Surpass USD 261.7 Billion by 2031

The global cancer immunotherapy market, valued at over USD 82.8 billion in 2021, is projected to experience robust growth with a CAGR of 13.6% from 2022 to 2031. This strong upward trajectory is driven by advancements in immuno-oncology, increased prevalence of cancer, and growing adoption of targeted therapies. By the end of 2031, the market is expected to surpass USD 261.7 billion, reflecting a significant shift toward more effective and personalized cancer treatments.

Immunotherapy is a cancer treatment that improves the immune system's ability to fight cancer. It is a kind of biological treatment. Biological therapy makes use of compounds derived from biological creatures or lab-created copies of these substances.

Unlock Full Market Insights: Get a Sample Report Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4312

Increase in R&D activities, improvements in efficacy & accuracy of newer medicines, surge in adoption of target therapy over standard therapy, and rise in prevalence of cancer are the major factors propelling the global cancer immunotherapy market. In addition, rise in incidence of cancer is a key factor driving the global cancer immunotherapy market. In the U.S., cancer is the biggest cause of mortality and disease, and it not only has a significant effect on the health of patients and survivors, but also has a major financial impact.

Market Segmentation

The cancer immunotherapy market can be segmented across various crucial parameters:

By Therapy Type (Service Type):

Monoclonal Antibodies: This segment currently dominates the market, largely due to extensive R&D investments in bispecific, conjugated, and naked antigen-binding antibodies. They are highly effective due to their targeted nature, high prescription rates, and minimal side effects.

Immune Checkpoint Inhibitors: This segment, including PD-1/PD-L1 and CTLA-4 inhibitors, is expected to witness significant demand due to their higher success rates and overall efficiency in blocking proteins that prevent the immune system from attacking cancer.

Immune System Modulators: These therapies work by broadly enhancing the immune system's ability to fight cancer.

Cancer Vaccines: These aim to train the immune system to recognize specific cancer antigens.

Adoptive Cell Therapies (e.g., CAR-T Cell Therapy): A breakthrough technology involving genetically modifying a patient's own immune cells to target cancer.

Oncolytic Virus Therapy: Utilizes viruses engineered to infect and kill cancer cells selectively.

Cytokine Therapy: Uses cytokines, proteins that regulate immune responses, to stimulate anti-tumor activity.

Others
By Sourcing Type (Drug Type - often refers to the core therapeutic agent):
Monoclonal Antibodies
Immunomodulators
Oncolytic Viral Therapies and Cancer Vaccines
Others

By Application (Therapeutic Area):

Lung Cancer: Expected to maintain its dominant position due to high incidence and robust research pipeline.

Breast Cancer: Projected to be the fastest-growing segment, driven by high prevalence, ongoing R&D, and increased investments.

Colorectal Cancer
Melanoma
Prostate Cancer
Head & Neck Cancer
Blood Cancers (e.g., Leukemia, Lymphoma, Multiple Myeloma)
Stomach Cancer
Others (including Ovarian, Cervical, Kidney, Liver, Bladder, Pancreatic, and other cancers)

By End-User (Industry Vertical):

Hospitals & Clinics: The largest end-user segment, driven by rising cancer incidence, increased treatment rates, and the availability of immunotherapy treatments across numerous hospitals.

Cancer Research Centers: Anticipated to record significant growth due to ongoing R&D activities.

Ambulatory Surgical Centers (ASCs)
Specialty Clinics

Regional Analysis

Geographically, the global cancer immunotherapy market is diverse, with key regions contributing significantly to its growth:

North America: Dominates the market, holding a substantial market share (e.g., 45.6% in 2023). This is attributed to the high incidence of cancer, rapid adoption of advanced immunotherapies, robust healthcare infrastructure, favorable reimbursement policies, and significant investments in R&D, particularly in the United States.

Europe: A significant market driven by increasing cancer cases, technological advancements, and supportive government initiatives.

Asia Pacific: Expected to be the fastest-growing market (e.g., CAGR of 11.3% from 2024-2030), primarily due to a rising population of cancer patients, increasing healthcare expenditures, and growing awareness of innovative therapies in countries like China, India, and Japan. India's market, for instance, is projected to reach US$ 9,004.2 million by 2030 with a CAGR of 15.2%.

Latin America: Shows emerging opportunities for growth.

Middle East & Africa: The Middle East healthcare market is growing rapidly, with increased investment in the pharmaceutical sector and rising awareness of advanced cancer treatments driving the adoption of immunotherapy.

Market Drivers and Challenges

Market Drivers:

Rising Cancer Incidence: The increasing global burden of cancer due to various factors including aging populations, lifestyle changes, and environmental factors is the primary driver.

Advancements in Immunotherapy: Continuous breakthroughs in drug development, particularly in checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines, are expanding treatment options and improving outcomes.

Growing Preference for Targeted Therapies: Patients and clinicians increasingly prefer treatments that offer precise targeting and fewer side effects compared to traditional methods.

Increasing Investment in R&D: Pharmaceutical companies, academic institutions, and governments are investing heavily in cancer immunotherapy research, accelerating the discovery and development of new therapies.

Supportive Regulatory Environment: Favorable regulatory policies and quicker drug approvals are facilitating market expansion.

Growth in Personalized Medicine: The ability to tailor treatments based on an individual's genetic makeup and tumor profile enhances treatment efficacy and drives adoption.

Combination Therapies: The use of immunotherapy in combination with other treatments like chemotherapy or radiation is showing promising results, enhancing efficacy and overcoming resistance.

Emergence of Biosimilars: Increasing emergence of biosimilars is expected to propel market growth by improving accessibility and affordability.

Market Challenges:

High Treatment Costs: The high cost of immunotherapy treatments remains a significant barrier, particularly in low-income and developing nations, limiting patient access.

Efficacy Predictability and Patient Response Variability: While highly effective for some, the efficacy of immunotherapies can be unpredictable, and not all patients respond well due to factors like tumor heterogeneity and underlying immunosuppressive biology.

Regulatory Complexities: The complex regulatory landscape for novel immunotherapies can pose challenges for market entry and widespread adoption.

Lack of Awareness and Accessibility: In some regions, a lack of awareness among patients and healthcare professionals, coupled with limited access to specialized infrastructure and skilled personnel, can hinder market penetration.
Immune-related Side Effects: While generally less severe than chemotherapy, immunotherapies can still cause immune-related adverse events.

Competition in Product Development: The intense competition in the product development cycle makes it challenging to develop new, high-quality drugs that address diverse cancer types and patient needs.

Market Trends

Emergence of Adoptive Cell Therapies (e.g., CAR-T cells): Continued innovation and increasing approvals for CAR-T cell therapies are reshaping the landscape for hematologic cancers and are being explored for solid tumors.

Development of Personalized Cancer Vaccines: Research into vaccines tailored to individual tumor neoantigens is a significant trend, offering highly specific immune responses.

Exploration of Oncolytic Viruses: These engineered viruses are gaining traction for their ability to selectively target and kill cancer cells while stimulating an anti-tumor immune response.

Utilization of Artificial Intelligence (AI) in Immunotherapy Research: AI and machine learning are being increasingly used to accelerate drug discovery, identify biomarkers, and optimize treatment plans.

Increasing Emphasis on Real-World Evidence (RWE): Gathering RWE is becoming crucial for understanding long-term efficacy and safety of immunotherapies in diverse patient populations.

Focus on Combination Therapies: A major trend is the development and clinical testing of various combination regimens to improve efficacy, overcome resistance, and expand therapeutic indications.

Advancements in Biomarker Identification: Improved biomarker discovery and utilization are critical for patient selection and predicting response to immunotherapy.

Growth in Oral Immunotherapeutic Drugs and Outpatient Care: A shift towards more convenient administration methods and settings is driving growth in retail pharmacies and outpatient care.

Future Outlook

The future of the cancer immunotherapy market looks exceedingly promising. Continued advancements in understanding tumor immunology, the development of novel targets, and the integration of cutting-edge technologies like gene editing and nanotechnology will further enhance treatment precision and overcome resistance. Immunotherapy is anticipated to become the standard treatment for an increasing number of cancer types, moving from advanced stages to earlier lines of therapy. The focus on precision medicine and individualized treatments, coupled with growing investments in emerging markets, will open up significant opportunities.

Key Market Study Points

Analyzing market size and growth forecasts from 2022 to 2031.
Detailed segmentation by therapy type, application, and end-user.

In-depth regional analysis, highlighting growth drivers and opportunities.

Identification of key market drivers, challenges, and emerging trends.

Assessment of the competitive landscape and strategic initiatives of key players.

Examination of regulatory frameworks, approval pathways, and government support.

Insights into technological advancements such as AI in drug discovery and personalized medicine.

Competitive Landscape

The cancer immunotherapy market is highly competitive, featuring a mix of established pharmaceutical giants and innovative biotech companies. Key players are actively engaged in R&D, strategic collaborations, mergers, and acquisitions to strengthen their product portfolios and market presence.

Some of the prominent companies shaping the market include:

Amgen, Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc (GSK)
Janssen Biotech, Inc. (Johnson & Johnson)
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Sanofi
Spectrum Pharmaceuticals, Inc.
Takeda Pharmaceuticals

These companies are continuously striving to introduce novel immunotherapies, expand therapeutic indications, and improve the efficacy of existing treatments through combination therapies and personalized approaches.

Recent Developments

Clinical Breakthroughs: Continued advancements are being reported, such as the development of drugs like dostarlimab showing significant efficacy against rectal cancer (June 2022).

Increased FDA Approvals: The US FDA approved 34 cancer immunotherapies in 2023, showcasing the rapid pace of innovation and regulatory support.

Growing Adoption of CAR-T Cell Therapies: CAR-T therapies, such as Novartis's Kymriah, continue to gain traction and receive approvals for various hematologic cancers.

Investment in Personalized Vaccines: Research and development into personalized cancer vaccines are gaining momentum, aiming to tailor treatments to individual patients.

Rise of Combination Therapies: The focus on combining immunotherapies with other treatments (chemotherapy, radiation, targeted therapies) is a major trend to enhance efficacy and overcome resistance mechanisms.

Advancements in AI and Data Analytics: Integration of AI and machine learning tools is accelerating immunotherapy research, from target identification to treatment optimization.

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=4312

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.